Table 2.

Treatment characteristics of the eligible studies

StudyClinical stageChemotherapy regimens (mg/m2)No. of planned cyclesNo. of patientsNo. of pCR
Logothetis (30)T3b-4a,N0,M0MVAC (M 30, V 3, D 30, C 70)2RC: 48RC: 1 (2.1%)
MVAC: 51MVAC: 14 (27.5%)
ICT (31)T2-4a, N0, M0CMV (M 30, V 4, C 100)3RC: 211RC: 26 (12.3%)
CMV: 206CMV: 67 (32.5%)
Sherif (32)T2-4a, N0, M0CM (M 250, C 100)3RC: 139RC: 16 (11.5%)
CM: 140CM: 37 (26.4%)
Grossman (14)T2-4a, N0, M0MVAC (M 30, V 3, D 30, C 70)3RC: 121RC: 18 (14.9%)
MVAC: 126MVAC: 48 (38.1%)
Dash (18)T2-4a, N0, M0GC (G 1000, C 35)GC: 4GC: 42GC: 11 (26.2%)
MVAC (M 30, V 3, D 30, C 70)MVAC: 4MVAC: 33MVAC: 9 (27.3%)
Kaneko (19)T1-4, Nany, M0GC (G 1000, C 70)GC: 2GC: 22GC: 10 (45.5%)
MVAC (M 30, V 3, D 30, C 70)MAVC: 2MVAC: 9MVAC: 2 (22.2%)
Pal (21)NAGC (NA)GC: 3–4GC: 24GC: 6 (25%)
MVAC (NA)MVAC: 3–4MVAC: 22MVAC: 4 (18.2%)
Scosyrev (20)T2-4, Nany, M0GC (G 2000, C 70)2–4RC: 135RC: 7 (5.2%)
GC: 25GC: 5 (20%)
Yeshchina (22)T2-4a, N0-2, M0GC (NA)GC: NAGC: 16GC: 4 (25%)
MVAC (NA)MVAC: NAMVAC: 45MVAC: 14 (31.1%)
Fairey (26)T2-4, N0, M0GC (NA)GC: 4GC: 58GC: 12 (20.7%)
MVAC (NA)MVAC: 4MVAC: 58MVAC: 6 (10.3%)
Kitagawa (24)T2-4, N0, M0MVAC (M 30, V 3, D 30, C 70)2RC: 25RC: 0 (0%)
MVAC: 58MVAC: 15 (25.9%)
Lee (25)T2-4, N0, M0GC (NA)GC: NARC: 91RC: 8 (8.8%)
MVAC (NA)MVAC: NAGC: 41GC: 12 (29.3%)
MVAC: 31MVAC: 7 (22.6%)
Matsubara (23)T2-4, N0-2, M0GC (G 1000, C 70)4RC: 17RC: 0 (0%)
GC: 25GC: 10 (40%)
El-Gehani (27)T2-4, N0, M0GC (G 1250, C 70)4RC: 69RC: 2 (2.9%)
GC: 91GC: 19 (20.9%)
Kitamura (33)T2-4a. N0, M0MVAC (M 30, V 3, D 30, C 70)2RC: 65RC: 6 (9.2%)
MVAC: 59MVAC: 22 (37.3%)
Gandhi (29)T1-4, N0-2, M0GC (G 1000, C 70)VariableRC: 121RC: 8 (6.6%)
GC: 150GC: 34 (22.7%)
Zargar (28)T2-4a, N0, M0GC (NA)VariableGC: 602GC: 144 (23.9%)
MAVC (NA)MVAC: 183MVAC: 45 (24.6%)

Abbreviations: ICT, international collaboration of trialists; NA, not available.